Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
US Health Official Says Updated COVID-19 Boosters Should Offer Protection Amid Tracking Emerging Variants
The U.S. health officials are tracking several coronavirus omicron subvariants that more easily evade immunity, rendering many treatments ineffective.
But the new booster shots should provide protection, said Dr. Ashish Jha, head of the White House Covid task force.
